Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NCI

- PMLiVE

AZ swells immuno-oncology pipeline with Innate deal

Deal gives access to natural killer cell immunotherapy

- PMLiVE

Merck’s Bavencio joins first-line kidney cancer face-off

PD-L1 and TKI combination could challenge standard of care

- PMLiVE

Lonely planet: why there is dwindling value in pharma travelling alone

To develop sustainable business models that establish value ‘beyond the pill’, collaboration is the best way forward

- PMLiVE

Dynavax is ‘deal-ready’ after solid ESMO data; analyst

Contrasting results for two novel immunotherapies

- PMLiVE

US says medicine ads should include list prices

Hopes the proposal will encourage lower prescription drug prices

- PMLiVE

Cancer care – the power of new technologies

With patient numbers set to soar, how can we make a difference?

- PMLiVE

AcelRX’s potent opioid tablets set to win FDA backing for pain relief

Panel voted 10 to 3 in favour of the treatment

- PMLiVE

BMS finds a new immunotherapy partner with $12m Compugen deal

Combination with novel antibody targeting PVRIG pathway

- PMLiVE

A look ahead to key trial readouts at ESMO

New combinations and novel mechanisms on show

- PMLiVE

RET rivals Loxo and Blueprint face off with early-stage data

No clear winner between RET inhibitor rivals

- PMLiVE

Chinese biotech’s global ambitions

BeiGene aims to be the first home-grown big biopharma

- PMLiVE

Novartis files for approval of MS drug in EU, US

Siponimod could achieve blockbuster status if approved, says analysts

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links